现代医院
現代醫院
현대의원
MODERN HOSPITAL
2014年
7期
36-37,40
,共3页
陈林%刘日光%陈浩雄%陈磊%傅君舟
陳林%劉日光%陳浩雄%陳磊%傅君舟
진림%류일광%진호웅%진뢰%부군주
碳酸镧%高磷血症%透析%磷结合剂
碳痠鑭%高燐血癥%透析%燐結閤劑
탄산란%고린혈증%투석%린결합제
lanthanum carbonate%hyperphosphatemia%dialysis%phosphate binder
目的:探讨碳酸镧对维持透析患者高磷血症的短期疗效及耐受性。方法回顾性分析2012年10月~2013年10月在我院使用碳酸镧治疗高磷血症透析患者(血液透析或腹膜透析)的临床资料。结果共入组22例患者,其中男13例,女9例,腹膜透析4例,血液透析18例,平均年龄(54.2±15.1)岁,平均透析龄(51.5±21.4)月。治疗前、治疗12周后血磷,血清校正钙、钙磷乘积、iPTH为:(2.94±0.43) vs(2.31±0.39)(p=0.00),(2.23±0.11) vs(2.26±0.10)(p=0.25),(82.2±12.9) vs(65.3±11.1)(p=0.00),(1462±1053) vs(1411±943)(p=0.51)。不良反应主要为胃肠道反应,发生率36.4%,无1例患者因严重不良反应退出。结论碳酸镧是一种对维持透析患者短期疗效好、不良反应轻,耐受性良好的口服磷结合剂。
目的:探討碳痠鑭對維持透析患者高燐血癥的短期療效及耐受性。方法迴顧性分析2012年10月~2013年10月在我院使用碳痠鑭治療高燐血癥透析患者(血液透析或腹膜透析)的臨床資料。結果共入組22例患者,其中男13例,女9例,腹膜透析4例,血液透析18例,平均年齡(54.2±15.1)歲,平均透析齡(51.5±21.4)月。治療前、治療12週後血燐,血清校正鈣、鈣燐乘積、iPTH為:(2.94±0.43) vs(2.31±0.39)(p=0.00),(2.23±0.11) vs(2.26±0.10)(p=0.25),(82.2±12.9) vs(65.3±11.1)(p=0.00),(1462±1053) vs(1411±943)(p=0.51)。不良反應主要為胃腸道反應,髮生率36.4%,無1例患者因嚴重不良反應退齣。結論碳痠鑭是一種對維持透析患者短期療效好、不良反應輕,耐受性良好的口服燐結閤劑。
목적:탐토탄산란대유지투석환자고린혈증적단기료효급내수성。방법회고성분석2012년10월~2013년10월재아원사용탄산란치료고린혈증투석환자(혈액투석혹복막투석)적림상자료。결과공입조22례환자,기중남13례,녀9례,복막투석4례,혈액투석18례,평균년령(54.2±15.1)세,평균투석령(51.5±21.4)월。치료전、치료12주후혈린,혈청교정개、개린승적、iPTH위:(2.94±0.43) vs(2.31±0.39)(p=0.00),(2.23±0.11) vs(2.26±0.10)(p=0.25),(82.2±12.9) vs(65.3±11.1)(p=0.00),(1462±1053) vs(1411±943)(p=0.51)。불량반응주요위위장도반응,발생솔36.4%,무1례환자인엄중불량반응퇴출。결론탄산란시일충대유지투석환자단기료효호、불량반응경,내수성량호적구복린결합제。
Objective To Investigate the short-term efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia in dialysis patients.Methods The clinical data of dialysis patients ( hemodialysis or peritoneal dialysis) with hyperphosphatemia who were given with lanthanum carbonate treatment from October 2012 to October 2013 in our hospi-tal were retrospectively analyzed.Results A total of 22 cases were enrolled.Of all the 22 cases, there were 13 cases of males, 9 cases of females; 4 cases of peritoneal dialysis, and 18 cases of hemodialysis.Their average age was (54.2 ± 15.1) years, and their average dialysis age was (51.5 ±21.4) months.Before the treatment and 12 weeks after the treat-ment, serum phosphorus, corrected serum calcium, calcium-phosphorus product and iPTH were (2.94 ±0.43) vs (2.31 ± 0.39) (p=0.00), (2.23 ±0.11) vs (2.26 ±0.10) (p=0.25), (82.2 ±12.9) vs (65.3 ±11.1) (p=0.00), (1 462 ±1 053) vs 1 411 ±943) (p=0.51).The main adverse reactions were gastrointestinal reactions.The incidence of adverse effects was 36.4%.No patient quitted from this study for safety reason.Conclusion Lanthanum carbonate is a well-tolera-ted oral phosphate binder with a good short-term curative effect and light adverse reactions in treatment of hyperphosphatemia in dialysis patients.